Fresenius Medical Care AG (NYSE:FMS) was down 4.2% during mid-day trading on Friday . The company traded as low as $43.49 and last traded at $44.49, with a volume of 1,066,027 shares trading hands. The stock had previously closed at $46.42.

A number of equities research analysts have recently issued reports on FMS shares. Berenberg Bank reissued a “buy” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, August 9th. Jefferies Group raised shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research note on Friday, July 8th. Royal Bank Of Canada reissued a “hold” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, May 24th. Robert W. Baird reissued a “hold” rating on shares of Fresenius Medical Care AG in a research note on Monday, May 16th. Finally, Zacks Investment Research raised shares of Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. Fresenius Medical Care AG presently has an average rating of “Hold” and a consensus price target of $42.50.

The stock has a market capitalization of $27.32 billion and a P/E ratio of 24.77. The company has a 50-day moving average of $45.05 and a 200-day moving average of $43.44.

Fresenius Medical Care AG (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.92 by $0.04. The firm had revenue of $4.42 billion for the quarter, compared to analyst estimates of $4.54 billion. On average, equities analysts forecast that Fresenius Medical Care AG will post $2.01 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its stake in Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock valued at $4,493,000 after buying an additional 3,694 shares in the last quarter. Bank of Montreal Can boosted its stake in Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock valued at $2,373,000 after buying an additional 21,264 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock valued at $28,675,000 after buying an additional 116,653 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.